Society Testimony

Testimony to FDA on Testosterone

September 17, 2014

Endocrine Society Testimony to the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

"We recommend that treatment with testosterone be limited to men who meet established diagnostic guidelines for hypogonadism,, i.e., men who have clinical manifestations AND consistently low testosterone levels, and that treated patients be monitored as recommended by appropriate guidelines. We also recommend that more data be collected on men of different ages to better establish the serum testosterone thresholds for specific organ-related symptoms and signs, and to determine which clinical manifestations will benefit from replacement testosterone therapy. Finally, we recommend that a large scale, well controlled study be conducted to assess long term cardiovascular and prostate risks associated with testosterone replacement treatment."

arrowRead the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.